[Ischemic stroke patients following intravenous thrombolysis. Outcome in a regional stroke center].

G Pawlik, B Wagner, M Schabet
Author Information
  1. G Pawlik: Neurologische Klinik, Klinikum Ludwigsburg, Posilipostr. 4, 71640, Ludwigsburg, Deutschland. georg.pawlik@kliniken-lb.de

Abstract

BACKGROUND: We wanted to compare the outcome following IV thrombolysis in our patients with ischemic stroke with the outcome reported from the phase 3 registration trials and other large trials.
PATIENTS AND METHODS: From January 2008 through December 2009 we treated 225 patients with ischemic stroke with IV thrombolysis. Retrospectively, we analyzed their clinical data upon admission, during their stay, and upon discharge with special reference to eligibility criteria for IV thrombolysis, symptomatic hemorrhage, and clinical outcome.
RESULTS: The average age of the patients was 74 years, with 34% being older than 80 years. The median time between stroke onset and initiation of treatment was 112 min. The initial median NIHSS was 11 points (Rankin score  ≥ 4 in 79% of patients). The rate of symptomatic hemorrhage was 3%. The median follow-up was 14 days. At the end of the observation period, clinical symptoms had improved in 73% of patients (Rankin score  ≤ 2 in 45% of patients). The mortality rate was 12%. In 55% of patients, IV thrombolysis was off label (age  > 80 years in 34% of patients).
CONCLUSION: The clinical results of IV thrombolysis in our stroke center are similar to the outcome reported from the registration trials and larger clinical series although we treated off label in more than half of the patients. Even larger studies have since shown that the age limit under 80 years for patients is not reasonable. The eligibility criteria should be adapted to reality at this point.

References

  1. JAMA. 1995 Oct 4;274(13):1017-25 [PMID: 7563451]
  2. JAMA. 2000 Mar 1;283(9):1145-50 [PMID: 10703776]
  3. J Neurol Neurosurg Psychiatry. 2006 Jul;77(7):826-9 [PMID: 16505004]
  4. JAMA. 1999 Dec 1;282(21):2019-26 [PMID: 10591384]
  5. CMAJ. 2005 May 10;172(10):1307-12 [PMID: 15883405]
  6. J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):690-3 [PMID: 17056623]
  7. N Engl J Med. 1995 Dec 14;333(24):1581-7 [PMID: 7477192]
  8. Stroke. 2010 Aug;41(8):1833-5 [PMID: 20576948]
  9. N Engl J Med. 2008 Sep 25;359(13):1317-29 [PMID: 18815396]
  10. Lancet. 2007 Jan 27;369(9558):275-82 [PMID: 17258667]
  11. BMJ. 2010 Nov 23;341:c6046 [PMID: 21098614]
  12. Lancet. 1998 Oct 17;352(9136):1245-51 [PMID: 9788453]
  13. Nervenarzt. 2005 Feb;76(2):181-5 [PMID: 15300319]

MeSH Term

Age Distribution
Aged
Brain Ischemia
Comorbidity
Female
Fibrinolytic Agents
Germany
Hemorrhage
Humans
Injections, Intravenous
Male
Prevalence
Regional Medical Programs
Risk Assessment
Risk Factors
Stroke
Thrombolytic Therapy
Treatment Outcome

Chemicals

Fibrinolytic Agents

Word Cloud

Created with Highcharts 10.0.0patientsthrombolysisstrokeIVclinicaloutcometrialsagemedianfollowingischemicreportedregistrationtreateduponeligibilitycriteriasymptomatichemorrhage34%80 yearsRankinscoreratelabellargerBACKGROUND:wantedcomparephase3largePATIENTSANDMETHODS:January2008December2009225RetrospectivelyanalyzeddataadmissionstaydischargespecialreferenceRESULTS:average74 yearsoldertimeonsetinitiationtreatment112 mininitialNIHSS11points ≥ 479%3%follow-up14 daysendobservationperiodsymptomsimproved73% ≤ 245%mortality12%55% > 80 yearsCONCLUSION:resultscentersimilarseriesalthoughhalfEvenstudiessinceshownlimitreasonableadaptedrealitypoint[IschemicintravenousOutcomeregionalcenter]

Similar Articles

Cited By